Objective: To assess the prevalence of psychotic symptoms among youths (14-25 years of age) with a childhood diagnosis of attention-deficit/hyperactivity disorder (ADHD) combined type.
Method: Participants in the Multimodal Treatment Study of Children with ADHD (MTA) and a local normative comparison group (LNCG) were systematically assessed 6, 8, 10, 12, 14, and 16 years after the original enrollment at a mean age of 8.5 years. Trained research assistants administered a psychosis screener, and positive screens were referred to study clinicians to confirm or exclude psychosis. Possible associations between screening positive and alcohol or substance use were assessed.
Results: Data were available from 509 MTA participants (88% of original MTA sample; mean age 25.1 years) and 276 LNCG participants (96% of original sample; mean age 24.6 years) at year 16. Twenty-six MTA participants (5%; 95% CI 3-7) and 11 LNCG participants (4%; 95% CI 2-6) screened positive for at least 1 psychotic symptom (p = .60). Most psychotic symptoms were transient. The prevalence of clinician-confirmed psychotic symptoms was 1.1% (95% CI 0.2-2.1) in the MTA group and 0.7% (0-1.7) in the LNCG (p = .72). Greater cannabis use was reported by those who screened positive (p < .05) and were confirmed positive (p < .01).
Conclusion: There was no evidence that ADHD increased the risk for psychotic symptoms. In the ADHD and normative comparison groups, more frequent cannabis use was associated with a greater likelihood of experiencing psychotic symptoms, thus supporting the recommendation that youth should not use cannabis.
Keywords: attention-deficit/hyperactivity disorder; cannabis; psychosis; screening.
Published by Elsevier Inc.
Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study.J Child Psychol Psychiatry. 2018 Jun;59(6):692-702. doi: 10.1111/jcpp.12855. Epub 2018 Jan 8. J Child Psychol Psychiatry. 2018. PMID: 29315559 Free PMC article. Clinical Trial.
Functional Adult Outcomes 16 Years After Childhood Diagnosis of Attention-Deficit/Hyperactivity Disorder: MTA Results.J Am Acad Child Adolesc Psychiatry. 2016 Nov;55(11):945-952.e2. doi: 10.1016/j.jaac.2016.07.774. Epub 2016 Sep 2. J Am Acad Child Adolesc Psychiatry. 2016. PMID: 27806862 Free PMC article.
Risk for emerging bipolar disorder, variants, and symptoms in children with attention deficit hyperactivity disorder, now grown up.World J Psychiatry. 2015 Dec 22;5(4):412-24. doi: 10.5498/wjp.v5.i4.412. eCollection 2015 Dec 22. World J Psychiatry. 2015. PMID: 26740933 Free PMC article.
Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap.Can J Psychiatry. 2015 Mar;60(3 Suppl 2):S48-52. Can J Psychiatry. 2015. PMID: 25886680 Free PMC article. Review.
Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective.Postgrad Med. 2009 May;121(3):73-82. doi: 10.3810/pgm.2009.05.2005. Postgrad Med. 2009. PMID: 19491543 Review.
- Z99 MH999999/ImNIH/Intramural NIH HHS/United States
- HHSN271200800003C/DA/NIDA NIH HHS/United States
- U01 MH050467/MH/NIMH NIH HHS/United States
- HHSN271200800006C/DA/NIDA NIH HHS/United States
- U01 MH050453/MH/NIMH NIH HHS/United States
- N01MH12008/MH/NIMH NIH HHS/United States
- U01 MH050461/MH/NIMH NIH HHS/United States
- N01 MH012007/MH/NIMH NIH HHS/United States
- HHSN271200800004C/DA/NIDA NIH HHS/United States
- U01 MH050440/MH/NIMH NIH HHS/United States
- N01MH12004/MH/NIMH NIH HHS/United States
- N01 MH012010/MH/NIMH NIH HHS/United States
- HHSN271200800009C/DA/NIDA NIH HHS/United States
- HHSN271200800005C/DA/NIDA NIH HHS/United States
- N01MH12009/MH/NIMH NIH HHS/United States
- HHSN271200800008C/DA/NIDA NIH HHS/United States
- N01MH12012/MH/NIMH NIH HHS/United States
- HHSN271200800007C/DA/NIDA NIH HHS/United States
- R01 DA039881/DA/NIDA NIH HHS/United States